KARD — Kardigan, Inc.
$12.80+0.47%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for KARD in the TickerWise workspace.
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 210
- Website: http://www.kardigan.bio
Latest SEC filings for KARD
Latest KARD news
- Kardigan Announces Appointment of Kristin Reinke to its Board of Directors Read article
- Kardigan, Inc. (NASDAQ:KARD) Stock Has Consensus Price Target of $42.25 According to Analysts Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.